Mair Therapeutics is a biotech startup focused on developing therapies for neurodegenerative diseases, beginning with Parkinson's. Based in Nijmegen, Netherlands, the company integrates advanced computational models and ion channel research to identify promising drug targets. Their work primarily revolves around TMEM175, a lysosomal ion channel linked to Parkinson's, which regulates key cellular processes. Mair collaborates with local research institutions and has secured pre-seed funding to advance its work in drug discovery.